Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: Results of a 5-year follow-up in the LOTUS trial

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 10, 2012, Pages 959-971

  Fiocca, R ^a   Mastracci, L ^a   Attwood, S E ^b   Ell, C ^c   Galmiche, J P ^d   Hatlebakk, J ^e   Barthel A ^f   Langstrom G ^f   Lind, T ^f   Lundell, L ^g  

^a UNIVERSITY OF GENOA   (Italy)

^b NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d HÔTEL DIEU   (France)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f ASTRAZENECA R AND D   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN;

ADULT; AGED; ANTIREFLUX OPERATION; ARTICLE; CELL DENSITY; CELL STRUCTURE; CHROMOGRANIN A BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; ENDOCRINE CELL; EXOCRINE CELL; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE METAPLASIA; LAPAROSCOPIC ANTIREFLUX SURGERY; LAPAROSCOPIC SURGERY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOMACH ANTRUM; STOMACH ATROPHY; STOMACH BIOPSY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; CHROMOGRANIN A; ENTEROCHROMAFFIN-LIKE CELLS; ESOMEPRAZOLE SODIUM; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867574793     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12052     Document Type: Article

References (50)

1. Kuipers EJ, Uyterlinde AM, Pena AS, et al,. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
2. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E,. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53. (Pubitemid 28160019)
3. Wilder-Smith CH, Spirig C, Krech T, Merki HS,. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 1992; 4: 885-91.
4. Gianella RA, Broitman SA, Zamcheck N,. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut 1972; 13: 251-6.
5. Creuzfeldt W,. The achlorhydria-carcinoid sequence. Role of gastrin. Digestion 1988; 39: 61-79.
6. Hirschowitz BI, Haber MM,. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15: 87-103. (Pubitemid 32055589)
7. Jensen RT,. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19.
8. Klinkenberg-Knol EC, Nelis F, Dent J, et al,. Long-term omeprazole treatment in resistant gastresophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9. (Pubitemid 30171615)
9. Schenk BE, Kuipers EJ, Nelis GF, et al,. Effects of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-21. (Pubitemid 30305777)
10. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al,. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitits treated with omeprazole of fundoplication. N Engl J Med 1996; 334: 1018-22. (Pubitemid 26123777)
11. Waldum HL, Brenna E,. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000; 14: 15-22. (Pubitemid 30058156)
12. Gray JD, Shiner M,. Influence of gastric pH on gastric and jejunal flora. Gut 1967; 8: 574-81.
13. Houben GMP, Stockbrügger RW,. Bacteria in the aetio-pathogenesis of gastric cancer: a review. Scand J Gastroenterol 1995; 30 (Suppl. 212): 13-8.
14. Lundell L, Attwood S, Ell C, et al,. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008; 57: 1207-13.
15. Galmiche J-P, Hatlebakk J, Attwood S, et al,. Laparoscopic Antireflux Surgery vs esomeprazole treatment for chronic GERD. The LOTUS randomized clinical trial. JAMA 2011; 305: 1969-77.
16. Attwood S, Lundell L, Hatlebakk JG, et al,. Standardization of surgical technique in laparoscopic anti-reflux surgery: the LOTUS trial experience. World J Surg 2008; 32: 995-8.
17. Price AB,. The Sydney System: histological division. J Gastroenterol Hepatol 1991; 6: 209-22.
18. Solcia E, Rindi G, Havu N, Elm G,. Qualitative study on gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl 1989; 24: 129-37. (Pubitemid 19267375)
19. Rugge M, Correa P, Dixon MF, et al,. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 1249-59.
20. Filipe MI, Munoz N, Matko I, et al,. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57: 324-9. (Pubitemid 24168604)
21. Correa P, Cuello C, Duqque E,. Carcinoma and intestinal metaplasia in the stomach of Columbian migrates. J Natl Cancer Inst 1970; 44: 297-306.
22. Drasar BS, Shiner M, McLeod GM,. Studies on the intestinal flora. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology 1969; 56: 71-9.
23. Stockbrügger RW,. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol 1985; 20 (Suppl. 111): 7-16. (Pubitemid 15105118)
24. Yeomans ND, Brimblecombe RW, Elder J, et al,. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995; 40 (Suppl. 2): 81-95.
25. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH,. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-6.
26. Larkin CJ, Watson RGP, Sloan JM, Stevenson M, Ardill JES, Buchanan D,. Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol 2000; 35: 578-82. (Pubitemid 30441707)
27. Suzuki M, Miurq S, Suematsu M, et al,. Helicobacter pylori-associated ammonia production enhances neutrophili-dependent gastric mucosal cell injury. Am J Physiol 1992; 263: G719-25.
28. Tsujii M, Kavano S, Tsujii S, Fusamoto H, Kamada T, Sato N,. Mechanism of gastric mucosal damage induced by ammonia. Gastroenterology 1992; 102: 1881-8.
29. Ricci V, Sommi P, Fiocca R, et al,. Cytotoxity of Helicobacter pylori on human gastric epithelial cells in vitro: role of cytotoxin(s) and ammonia. Eur J Gastroenterol Hepatol 1993; 5: 687-94. (Pubitemid 23280333)
30. Chan WY, Hui PK, Leung KM,. Modes of Helicobacter pylori colonisation and gastric epithelial damage. Histopathology 1992; 21: 521-8. (Pubitemid 23005743)
31. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al,. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20. (Pubitemid 38083004)
32. Eissele R, Brunner G, Simon B, Solcia E, Arnold R,. Gastric mucosa during treatment with lansoprazole. Helicobacter pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology 1997; 112: 707-17. (Pubitemid 27113795)
33. Lundell L, Miettinen P, Myrvold HE, et al,. Lack of effects of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319-26. (Pubitemid 29352939)
34. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH,. Review article: potential gastro intestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68. (Pubitemid 30352732)
35. Yang Y-X, Metz DC,. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115-27.
36. Lundell L, Havu N, Miettinen P, et al,. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 639-47.
37. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H,. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther 2011; 33: 829-36.
38. Malfertheiner P, Megraud F, O'Morain C, Sugihara H, Hattori T,. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007; 56: 772-81. (Pubitemid 46854190)
39. Hagiwara T, Mukaisho K, Nakayama T, et al,. Long-term proton pump administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011; 60: 624-30.
40. Kuipers EJ, Uyterlinde AM, Pena AS, et al,. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6.
41. Cats A, Schenk BE, Bloemena E, et al,. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000; 31: 684-90. (Pubitemid 30445471)
42. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH,. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341-8. (Pubitemid 44571564)
43. Ally MR, Veerappan GR, Maydonovitch CL, et al,. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. Dig Dis Sci 2009; 54: 2617-22.
44. Bordi C, Ravazzola M, DeVita O,. Pathology of endocrine cells in gastric mucosa. Ann Pathol 1982; 3: 19-28.
45. Lodato F, Azzaroli F, Turco L, et al,. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010; 24: 193-201.
46. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E,. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100: 311-9.
47. HÅkanson R, Sundler F,. Mechanisms for the development of gastric carcinoids. Digestion 1986; 35 (Suppl. 1): 1-151.
48. Watkinson A, Dockray GJ,. Functional control of chromogranin A and B concentrations in the body of the rat stomach. Regul Pept 1992; 40: 51-61.
49. Sanduleanu S, De Bruine A, Stridsberg M, et al,. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-11. (Pubitemid 34203475)
50. Borch K, Stridsberg M, Burman P, Rehfeld JF,. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198-202. (Pubitemid 27105292)